Science Corporation Raises $400 Million at $3.5 Billion Value
The Series D round backs the company's brain-computer interface work, with its first product PRIMA already approved in Europe.
Updated on Nov. 17, 2026 in Biotech

Live Poll
Would you trust a brain implant to treat a serious medical condition?
Science Corporation, founded in 2021 by Max Hodak, raised a $400 million Series D round that investors valued at $3.5 billion. The funding was announced in a company blog post, and the valuation was disclosed by a person familiar with the deal.
Why it matters
The round gives the company capital to pursue U.S. regulatory approval for its PRIMA implant and to design early human trials of a bio-hybrid sensor built from cultured neurons and silicon. Its path to the U.S. market runs through the FDA's Humanitarian Device Exemption, which would make PRIMA available to American patients if granted.
The $400 million Series D was announced in a company blog post, and the $3.5 billion valuation was disclosed by a person familiar with the deal. Neither the prior valuation nor the expected timeline for FDA review of PRIMA has been disclosed.
The players
Science Corporation
A neurotechnology company founded in 2021 that is developing brain-computer interfaces, including the PRIMA implant.
Max Hodak
The founder of Science Corporation, who previously co-founded Neuralink's early research program.
Murat Günel
A Yale neurosurgery professor collaborating with Science Corporation on the initial human trials of its bio-hybrid sensor.
The details
Science Corporation's first product, PRIMA, is a wearable and implantable chip that is approved in Europe and available in Germany, and it is being trialled for Stargardt's disease. The company is also designing initial human trials of a bio-hybrid sensor with Yale neurosurgery professor Murat Günel, who said the device could offer potential treatments for Parkinson's disease and other brain injuries and illnesses.
Timeline
2021: Science Corporation was founded by Max Hodak.
November 17, 2026: The Series D funding and valuation were announced.
The Tech Race
The funding positions Science Corporation to extend PRIMA, already approved in Europe, into the U.S. market through the FDA's Humanitarian Device Exemption. The company's bio-hybrid sensor work moves it beyond current implants toward neurons cultured in the lab and combined with silicon.
For patients in the United States, PRIMA is not yet available, and access depends on whether the FDA grants the Humanitarian Device Exemption for the device. Patients with Stargardt's disease are the group currently being trialled, so the device's near-term relevance is limited to that population.
The takeaway
Monitor whether the FDA grants the Humanitarian Device Exemption for PRIMA, since that decision determines whether American patients gain access to the implant.
Further reading
For related coverage of neurotechnology and medical devices, see Biotech.
Live Poll
Would you trust a brain implant to treat a serious medical condition?






